Metabolic Health Dual GIP/GLP-1 receptor agonist
Expands the conversation from glucose control toward broader cardiometabolic and weight management.
Type 2 Diabetes Obesity
Explore Metabolic Health GLP-1 receptor agonist
Demonstrated cardiovascular benefit has influenced how and when it is used.
Type 2 Diabetes Obesity
Explore Metabolic Health Thyroid hormone receptor-β agonist
First approved pharmacotherapy for a common liver disease previously managed with lifestyle alone.
MASH
Explore Oncology Targeted cytotoxic conjugate
Reshaping treatment for biomarker-defined cancers, including 'HER2-low' disease.
Breast Cancer Lung Cancer
Explore Oncology Cell-cycle (CDK4/6) inhibitor
Improved outcomes in HR-positive breast cancer, including some early-stage settings.
Breast Cancer
Explore Neuroscience Anti-amyloid monoclonal antibody
Among the first disease-modifying approaches for early Alzheimer's, with real access debates.
Alzheimer's Disease
Explore Neuroscience CGRP pathway antagonist (mAb / gepant)
First migraine-specific preventive class in decades.
Migraine
Explore Respiratory Monoclonal antibodies (anti-IgE / IL-5 / IL-4Rα)
Enable targeted, phenotype-driven treatment for severe asthma.
Asthma
Explore Genetic Medicine Ex-vivo CRISPR/Cas9 gene editing
A milestone for genetic medicine, with major access and cost implications.
Explore